Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 2+2=5
The origninal agreement, which is the SEC doc I was referring to back in Feb 06 specifically joins S&L together and together they can not own more than 4.99%.  In the doc you reference they are changing the percentage. Don't see it as decoupling S&L. If that was the intent, I think we would need a new SEC filing splitting up the warrants into two separate entities.  
Share
New Message
Please login to post a reply